Dianthus Therapeutics Balance Sheet
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Dianthus Therapeutics financial position
At the end of fiscal 2025, Dianthus Therapeutics reported total assets of $530.9 million, up 42.0% from a year earlier against total liabilities of $37.5 million. Shareholders' equity stood at $493.4 million, or 92.9% of assets. The company held $51.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 13.32, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Dianthus Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 51.09M | 22.79M | 132.32M | 15.37M | 131.65M | 58.15M | 65.07M | 58.34M | 51.40M | 4.51M |
| Short-Term Investments | 353.21M | 252.45M | 41.39M | 60.13M | 45.28M | 90.68M | 80.66M | 84.22M | — | — |
| Receivables | 52.00K | 0 | 294.00K | 4.70M | — | — | — | — | — | — |
| Total Current Assets | 409.44M | 280.90M | 177.45M | 82.03M | 180.69M | 151.53M | 149.84M | 145.32M | 52.50M | — |
| Property, Plant & Equipment | 296.00K | 194.00K | 185.00K | 142.00K | 7.46M | 8.31M | 9.89M | 10.21M | 1.96M | — |
| Long-Term Investments | 110.14M | 81.73M | 0 | — | — | — | — | — | — | — |
| Total Assets | 530.92M | 374.01M | 179.41M | 83.11M | 189.93M | 161.62M | 161.51M | 157.31M | 54.46M | — |
| Accounts Payable | 9.72M | 4.58M | 2.61M | 1.17M | 3.04M | 3.76M | 2.81M | 3.49M | 167.00K | — |
| Total Current Liabilities | 30.73M | 18.45M | 9.63M | 8.22M | 10.86M | 11.43M | 14.12M | 10.42M | 4.14M | — |
| Total Liabilities | 37.52M | 21.53M | 10.54M | 9.45M | 17.26M | 17.71M | 20.32M | 11.66M | 4.14M | — |
| Shareholders' Equity | 493.40M | 352.48M | 168.87M | -44.37M | -17.25M | 143.91M | 141.19M | 145.65M | -42.12M | -8.87M |
| Retained Earnings | -336.73M | -174.39M | -89.42M | -45.87M | -325.57M | -254.43M | -179.50M | -102.73M | -45.21M | — |
| Net Cash (Debt) | 404.30M | 275.24M | 173.72M | 75.49M | 176.93M | 148.84M | 145.73M | 142.57M | 51.40M | 4.51M |
| Shares Outstanding | 43.22M | 31.12M | 14.82M | 875.28K | 58.80M | 48.53M | 39.26M | 33.31M | 2.35M | — |
This table shows 10 annual periods of Dianthus Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow DNTH's reporting calendar. What is a balance sheet?